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High current findings indicate that a substitution with pyruvate can lead to significant alterations 
or even improvement in neutrophil immunonutrition. However, it is still unknown which intra-
cellular pathways might be involved here. Hence, in this study, we investigated whether preincu-
bation with an inhibitor of •NO-synthase (L-NAME), an •NO donor (SNAP), an analogue of taurine 
(beta-alanine), an inhibitor of ornithine-decarboxylase (DFMO) as well as a glutamine-analogue 
(DON), is able to alter the intragranulocytic metabolic response to pyruvate, here for example stu-
died for neutrophil intracellular amino- and α-keto acid concentrations or important neutrophil 
immune functions [released myeloperoxidase (MPO), the formation of superoxide anions ( )2−O  
and hydrogen peroxide (H2O2)]. In summary, the interesting first results presented here showed, 
that any damage of specific metabolic pathways or mechanisms, which seem directly or indirectly 
to be involved in relevant pyruvate dependent granulocytic nutrient content or specific cellular 
tasks, could lead to therapeutically desired, but also to unexpected or even fatal consequences for 
the affected cells. We therefore continue to believe that pyruvate, irrespective of which exact bio-
chemical mechanisms were involved, in neutrophils may satisfy the substantial metabolic de-
mands for a potent intracellular nutrient. 
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Neutrophil granulocytes form an indispensable component of the innate immune system and are the most abun-
dant type of white blood cells in mammals, accounting for close to 60% - 70%. Being highly motile, they 
quickly congregate at a focal point of infection, attracted by cytokines expressed by activated endothelial and 
various other cells. After activation, neutrophils express and release cytokines, which in turn amplify inflamma-
tory reactions, and are capable of attacking microorganisms directly by use of three impressive weapons: pha-
gocytosis, release of soluble anti-microbials and generation of neutrophil extracellular fibre traps. 
However, the successful achievement of these tasks depends on one key requirement: the subtle and the espe-
cially undisturbed interplay of all relevant intracellular biochemical pathways. In fact, the cell is obviously 
equipped with an impressive arsenal of metabolic pathways capable of taking on the role of a highly effective 
immunological weapon. Examples here include the reversible transamination of pyruvate by the alanine amino-
transferase (producing alanine and α-ketoglutarate), the anaplerotic carboxylation of pyruvate metabolized by 
pyruvate carboxylase (which provides oxalacetate precursors for the citric acid cycle and gluconeogenesis), the 
“de novo synthesis”  of important sugars, amino and α-keto acids (i.e. glucose, alanine, α-ketoglutarate, arginine, 
ornithine, etc.) or the ability to form energy-rich molecules such as nicotinamide adenine dinucleotide phosphate 
(NADPH) or guanosine-5'-triphosphate (GTP) from pyruvate-depent pathways, and so on [1]-[6]. Simply one of 
the most important biochemical processes in which pyruvate is involved, the conversion of pyruvate by the py-
ruvate dehydrogenase complex (PDH) to form acetyl-CoA, an important link substrate between the metabolic 
pathways of glycolysis and the citric acid cycle, was, actually and not really surprising to the concerned viewer, 
also found in neutrophils [7]-[10]. 
So it is not surprising that pyruvate, or simple pyruvate-dependent derivatives (i.e. ethyl-pyruvate) which are 
preferred due to known galenic problems in vivo, is moved as a potential metabolic substrate into the focus of 
scientific immunonutrition research. And observing the first interesting results, there seems to be little doubt: 
pyruvate, whose name is derived from the greek “pyr” (fire, heat) and the latin “uva” (grape), indeed, impres-
sively fulfills the criteria for a potent molecule in modulation of endogenous immunoregulation and also seems 
to play a relevant role in granulocytic host defence mechanisms, of course taking advantage of existing extra- 
and intracellular α-keto and amino acid pathways [11]-[13]. 
But if one looks, however, at the current results available so far, another fact is unfortunately recognizable: 
detailed studies about possible immunonutritional effects of pyruvate or pyruvate-dependent derivatives of the 
amino or α-keto acid content or metabolism in neutrophils or are not yet available [5] [14]. An example is glu-
tamine metabolism in neutrophils. Here it remains entirely unclear whether an inhibitor of glutamine-requiring 
enzymes may especially influence pyruvate-induced metabolic and immunological effects [15]. The same ap-
plies to other metabolic pathways which are particularly significant for neutrophils: for example the question 
whether the effects of pyruvate on neutrophil metabolism and immune functionality are modulated by alterations 
in intracellular amino or α-keto acid pathways, which are related with nitric oxide (•NO), ornithine, arginine or 
taurine content, metabolism or transport [11] [16]-[21]. 
The design of our new study was therefore to document and compare the effects of various metabolic mod-
ulators on neutrophil amino acid and α-ketoacid concentrations or important neutrophil immune functions [re-
leased myeloperoxidase (MPO), the formation of superoxide anions ( )2O−  and hydrogen peroxide (H2O2)], in 
order to investigate which pathways may be affected in a pyruvate-induced immunonutrition of neutrophils. In 
our study, it was of particular importance, that the metabolic modulators were preinvestigated adequately. For 
this reason we selected the following: Nω-nitro-L-arginine-methylester-hydrochloride [L-NAME, inhibitor of 
•NO-synthase], S-nitroso-N-acetyl-penicillamine [SNAP, •NO donor], 6-diazo-5-oxo-L-norleucine [DON, glu-
tamine-analogue], β-alanine [β-Ala, taurine-analogue] and α-difluoro-methyl-ornithine [DFMO, inhibitor of or-
nithine-decarboxylase]. 
2. Materials and Methods 
The study and the consent procedure was approved by the local ethics committee of the Justus Liebig University 
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Giessen, Germany (No. 69/99). The blood samples were taken in healthy volunteers, which appeared only for 
this cause in our research laboratory, and both the verbal consent as well as the personal and biometric data were 
accurately documented. After completion of the studies the volunteers received their test results with the 
screening of intra- and extracellular amino- and α-keto acids for their own medical documentation. Ten adult 
males between 25 and 46 years (34 ±  9.1) with an average height of 177.8 cm (range 171 - 188) and weight of 
81.7 kg (range 72 - 96) were selected. Those men with metabolic (e.g. diabetes, etc.), cardiopulmonary, neuro-
logical or allergic diseases or men taking drugs were excluded. Whole blood samples (lithium-heparinate plastic 
tubes) were withdrawn between 08:00 and 09:00 (after 10 hours of fasting) with consideration of circadian vari-
ations. P ≤ 0.05 was considered statistically significant. 
2.1. Pyruvate (PYR) Combined with L-NAME, SNAP, DON, β-Ala or DFMO 
Whole blood samples were incubated with aqueous solutions of pyruvate (PYR, 1 mM, Fresenius, Bad Hom-
burg, Germany) stabilized conscientiously for medical use due to known galenic problems (pH 4.5, Na+: 20 mM 
[22]) as well as with PYR (1 mM) + L-NAME (1 mM, Nω-nitro-L-arginine-methylester-hydrochloride; inhibi-
tor of nitric oxide (•NO) synthase; Calbiochem, Bad Schwalbach, Germany), PYR (1 mM) + SNAP (100 µM, 
S-nitroso-N-acetyl-penicillamine; exogenous nitric oxide donor (•NO-release: 5.6 µM/ min); Sigma, Deisen-
hofen, Germany), PYR (1 mM) + DON (100 µM, 6-diazo-5-oxo-L-norleucine; analogue of glutamine and in-
hibitor of glutamine-requiring enzymes; Sigma, Deisenhofen, Germany), PYR (1 mM) + β-Ala (10 mM, 
β-alanine; analogue of taurine and taurine transport antagonist; Sigma, Deisenhofen, Germany) or PYR (1mM) 
+ DFMO (1 mM, α-difluoro-methyl-ornithine; irreversible inhibitor of ornithine decarboxylase; Sigma, Deis-
enhofen, Germany). For the latter PYR was added after a 15-minute pre-incubation of L-NAME, SNAP, DON, 
β-Ala or DFMO, this mixture was incubated again for another 120 minutes. The selected PYR concentration 
corresponded to former pyruvate incubation in vitro results [12] [23]. 
All solutions were prepared and diluted in Hank’s balanced salt solution (HBSS; Sigma, Deisenhofen, Ger-
many) and the pH in the test solution was confirmed to be 7.4. One milliliter of whole blood was incubated with 
25 µl of test solution (final pyruvate concentrations were as described above) at 37˚C using a vibrating water 
bath. Corresponding volumes of HBSS were added to the control tubes. Before further processing all fractions 
were immediately cooled in an ice water bath at 4˚C and 100 µg/ml phenyl methyl sulfonyl fluoride (PMSF), 10 
µg/ml leupeptin, 10 µg/ml pepstatin, as well as 10 µg/ml antipain (all acquired from Sigma, USA) were added to 
each plastic heparin tube before the blood samples; these additions served to inhibit proteases. 
2.2. Highly Selective Separation of PMN from Whole Blood 
Precise details of our PMN-separation technique have been described previously. This method allows a very 
rapid and selective enrichment of neutrophils while preserving high cellular viability and integrity from very 
small quantities of whole blood [24]. Separation of PMN was accomplished using a cooled (4˚C) Percoll® - 
gradient (Pharmacia, Uppsala, Sweden). 4 ml portions (Σ = 12 ml) of cooled whole blood from each volunteer 
were overlaid onto previously prepared and precooled (4˚C) 70%/55% (in 0.9% NaCl) Percoll® -gradients before 
centrifugation at 350 ×g for 15 minutes at 4˚C (Biofuge® , Heraeus, Hanau, Germany). This separates the PMN 
as a small layer between the erythrocyte and monocyte layers. The PMN were carefully removed from the sam-
ple and suspended in 10 ml cooled (4˚C) phosphate buffered saline (PBS) stock buffer (diluted 1:10, v/v; 10 × 
PBS stock buffer, without Ca2+/Mg2+, Gibco, Karlsruhe, Germany). After a second centrifugation step (350 ×g 
for 5 min at 4˚C), the PBS buffer was discarded and the erythrocytes remaining in the sample were hypotonical-
ly lysed using 2 ml of cooled (4˚C) distilled water (Pharmacia, Uppsala, Sweden). After 20 seconds the PMN 
fraction was immediately brought back to isotonicity by the addition of 1 ml of 2.7% NaCl (Merck, Darmstadt, 
Germany) at 4˚C and resuspended by adding 10 ml of diluted stock PBS buffer. After a third centrifugation step 
(350 ×g for 5 min at 4˚C) the PBS buffer was discarded and the PMN fraction again resuspended (200 µl PBS 
buffer). Subsequently, all PMN fractions were combined and two aliquots of resuspended sample were removed 
for microscopy. On average, the cell fractionation procedure lasted 34 ± 4 min. Immediately after preparation, 
the extracted PMN samples were frozen at −80˚C before lyophilization (freeze dryer CIT-2® , Heraeus, Hanau, 
Germany). These conditions allowed for a PMN lysis which was not chemically mediated and guaranteed longer 
analyte stability during extended storage of the sample. Samples prepared in this manner were stored at −80˚C 
until analyzed within a period not exceeding four weeks. The purity, determined in duplicate in the first aliquot 
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by dyeing with “Türk’s Solution® ” (Merck) and viability, determined in the second aliquot by exclusion of 
“Trypan Blue® ”  (Merck) were examined and verified by light microscopy (Zeiss, Oberkochen, Germany). Cell 
yields were determined at the same time that viability was measured, samples with a PMN purity and viability < 
96% were discarded. In parallel, plasma samples (100 µl) were separated, lyophilized and stored using known 
techniques. 
2.3. Chromatographic Amino and α-Keto Acid Analysis 
Amino and α-keto acids in PMN were quantified using previously described methods which fulfilled the strict 
criteria required for ultrasensitive, comprehensive amino acid and α-keto acid analysis, specially developed and 
precisely validated in our institute for this purpose [14] [24] [25]. Moreover, the coefficients of variations for 
both method reproducibility and reproducibilities of retention times were also within normal ranges. PMN 
amino acid concentrations are given in 10−16 moles per neutrophil-cell, while PMN α-keto acid concentrations 
are given in 10−17 moles per neutrophil-cell. 
2.4. Preparation of Derivatization Reagent 
For the fluorescence labeling of the α-keto acids, we used ο-phenylenediamine (OPD, Sigma, Deisenhofen, 
Germany). Since oxidation of OPD influences the results in a negative way (the oxidized reagent causes varia-
tion in the fluorescence intensity) the brown powder must be re-crystallized prior to use. Although the amount of 
reactive OPD is less when using the oxidized form of the reagent, this re-crystallization procedure is necessary 
even when starting with the originally supplied substance. The o-phenylenediamine was dissolved in heptane at 
a temperature of 100˚C - 120˚C (oil bath, Merck) and the heptane subsequently evaporated in a rotary evapora-
tor (Merck). This procedure yielded a white powder after drying. With storage under N2 (Sigma, Deisenhofen, 
Germany) and at 4˚C in a dark bottle, the dry substance is useable for several months. For each batch of analyses, 
the OPD reagent must be freshly prepared. For each sample, 5 mg of OPD was dissolved in 5 ml of 3 M HCl 
(Sigma) and 10 µl of 2-mercaptoethanol (Sigma) was added to yield OPD-HCl-ME. This reagent solution was 
stable for several hours without loss of sensitivity. 
2.5. Standard Samples & Precolumn Derivatization Procedure 
Analytically pure α-keto acids (Sigma) were dissolved in distilled H2O (Merck) containing 4% human serum 
albumin (Merck), immediately lyophilized and stored at −80˚C. The lyophilizates (PMN, plasma and standard 
samples) were solubilized in 250 µl of pure methanol (Mallinckrodt Baker B.V., Deventer, Holland). The me-
thanol also contained the α-keto acid, α-ketovalerate (KV; Sigma) as an HPLC internal standard. KV is a 
non-physiological α-keto acid. After a 3-minute incubation and a 3-minute centrifugation step (3000 ×g, Rotix-
a/KS® , Tuttlingen, Germany), 200 µl of the extracts were dried under N2 (10 min, 20˚C, Messer, Griesheim, 
Germany). The OPD-HCl-ME reagent (5 ml) was then added, and the samples were incubated for 60 minutes at 
80˚C. The derivatization was stopped after exactly 60 minutes by cooling for 15 minutes in ice water. Ethyl ace-
tate (2 ml, Sigma) was added to the samples and mixed for 7 minutes in a rotary mixer (Merck) to extract the 
α-keto acids. After extraction, the top ethyl acetate layer was then transferred to a glass vial (2-CRV® , Chroma-
coll, Trumbull, USA). This procedure was repeated twice for each sample. The combined etylaceate portions 
were dried under N2 (30 min), re-solubilized in 120 µl of methanol and 50 µl of this mixture was injected onto 
the HPLC column. 
2.6. Fluorescence High-Performance Liquid Chromatography 
The fluorescence high-performance liquid chromatography system (F-HPLC) consisted of a pump with a con-
troller for gradient programming (600 E® , Waters, Milford, MA, USA) and a programmable autosampler (Tri-
athlon® , Spark, Netherlands) with a Rheodyne injection valve and a 100 µl sample loop (AS 300® , Sunchrom, 
Friedrichsdorf, Germany). A Nova-Pak® , 300 × 3.9 mm i.d., RP-C-18, 60Å, 4 µm (Waters) analytical column 
was used for separation. Column temperatures were maintained at 35˚C using a column oven (Knauer, Berlin, 
Germany). The column eluent was monitored using a fluorescence spectrophotometer (RF-530® , Shimadzu, 
Kyoto, Japan) at an excitation wavelength of 360 nm and an emission wavelength of 415 nm. Data recording 
and evaluation was performed using computer integration software (EuroChrom 2000® , Knauer, Berlin, Ger-
M. Deller et al. 
 
 161 
many). The linear calibration curves were constructed based on area ratios of the standard (St) to the sample (S) 
chromatogramms ([areaketo acid-St/ areainternal standard-St] × amount or concentration of keto acids injected = calcula-
tion factor (CF); [areaketo acid-S/ areainternal standard-S] × CF = final result). The flow rate was maintained at 1.0 ml/min 
throughout. For the gradient program and solvents, these were automatically degassed using a 3-channel de-
gasser (Knauer, Berlin, Germany). 
2.7. Superoxide Anion Production 
Superoxide anion and hydrogen peroxide production as well as activity of released myeloperoxidase were de-
termined photometrically using modifications of known methods validated in our institute for this purpose [14] 
[24] [25]. Superoxide anion production was measured by reduction of cytochrome C, 100 mg of cytochrome C 
(type IV, Sigma, Deisenhofen, Germany) which was dissolved in 30 mL PBS® -glucose buffer. The solution was 
aliquoted and frozen at −20˚C. Opsonized zymosan (Sigma, Deisenhofen, Germany) was used to stimulate PMN. 
It was produced by incubating 100 mg zymosan with 6 mL pool serum for 30 min at 37˚C. After washing with 
saline and centrifuging centrifugation at 350 ×g (10 min) opsonized zymosan was re-suspended in 10 mL PBS® - 
glucose buffer, aliquoted and frozen at −20˚C. The PMN were then isolated using a modification of our PMN- 
separation technique (as mentioned above). After stepwise (15 minutes and 5 minutes) centrifugation procedures 
(350 ×g, 20˚C) as well as careful lysis of a few erythrocytes contaminating the pellet, the pelleted PMN- cells 
were re-suspended by adding diluted PBS®  (Gibco, Karlsruhe, Germany) stock buffer. After 7 mL PBS®  stock 
buffer had been administered, the tube was centrifuged at 350 ×g for 5 minutes (20˚C). The supernatant was de-
canted. Samples with a PMN purity <96% and those with more than 4% of dead cells were discarded. The PMN 
concentration required in each case was adjusted by adding PBS containing 9.99 g glucose (Merck, Darmstadt, 
Germany). After PMN isolation, 500 µL zymosan, 150 µL pool serum, 250 µL cytochrom C and 500 µL iso-
lated PMN suspension (0.8 × 106/mL) and again the pyruvate to be tested, were poured into a test tube. A prep-
aration containing 500 µL buffer instead of zymosan was used as a zero adjustment. After further incubation for 
15 minutes at 37˚C the reaction was stopped by putting the test tube into ice water. After centrifugation (350 ×g; 
5 min, 4˚C) extinction of the supernatant was measured photometrically (546 nm; Digitalphotometer 6114S® ; 
Eppendorf, Germany). The amount of superoxide anion produced was calculated and resulted from the extinc-
tion coefficient of cytochrome C according to the Lambert-Beer law. All control probes obtained for standard 
curves have been prepared, incubated and measured identically. 
2.8. Hydrogen Peroxide Production 
Hydrogen peroxide production was also determined photometrically. The method was based on horseradish pe-
roxidase catalysed by oxidation of phenol red by hydrogen peroxide [14] [24] [25]. Phenol red (Sigma, Deisen-
hofen, Germany) and horseradish peroxidase (type II, Sigma, Deisenhofen, Germany) were added to PMN 
which had been stimulated by opsonized zymosan. Phenol red was dissolved in double-distilled water (10 g/L). 
Horseradish peroxidase was dissolved in PBS® -glucose buffer (5 g/L). After incubation of whole blood with 
pyruvate at 37˚C, PMN were isolated as described above. Isolated PMN were stimulated by opsonized zymosan 
(Sigma, Deisenhofen, Germany). The final test preparation consisted of 500 µL zymosan, 125 µL pool serum, 
12.5 µL horseradish peroxidase, 12.5 µL phenol red, 12.5 µL sodium azide (200mmol/L/l; Merck, Darmstadt, 
Germany), 500 µL PMN suspension (2 × 106 PMN-cells/mL) and again pyruvate. After incubation for 15 mi-
nutes (37˚C), the test preparation was centrifuged for 5 minutes (350 ×g; 4˚C). Subsequent to adding 25 µL so-
dium hydroxide solution (1.0 normal, Merck, Darmstadt, Germany) the extinction was measured photometrical-
ly at 623 nm. All control probes obtained for standard curves have been prepared, incubated and measured iden-
tically. 
2.9. Activity of Released Myeloperoxidase 
Activity of released myeloperoxidase was also determined photometrically [14] [24] [25]. 1 mmol/L 2.2’-azi- 
no-di-(3-ethylbenzthiazoline) sulphonic acid (ABTS, Sigma, Deisen-hofen, Germany) was dissolved in 0.1 
Mol/L citrate buffer (Behring, Marburg, Germany; pH 7.4). After incubation of whole blood with pyruvate at 
37˚C, 100 µL isolated PMN suspension (2 × 106/mL) was incubated with 0.5 µg cytochalasin B (Sigma, Dei-
senhofen, Germany) and again with pyruvate (5 min; 37˚C). After adding 100 µL opsonized zymosan and sup-
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plementing in order to keep the concentration constant, the preparation was incubated again for 10 min (37˚C). 
Then 1 mL ATBS solution was added. After centrifuging (700 ×g, 5 min, 20˚C) 1 mL of supernatant was re-
moved and mixed with 1 µL hydroxide peroxide solution (30%; Merck, Darmstadt, Germany) and extinction 
was measured photometrically (405 nm). 
2.10. Statistical Analysis 
Statistical analysis and interpretation of the results were performed in close co-operation with colleagues from 
the Department of Medical Statistics, Justus Liebig University Giessen, Germany. All tests were performed in 
duplicate. Thus our PMN amino acid results represent the mean of two estimations. After the results were dem-
onstrated to be normally distributed (Pearson-Stephens test), statistical methods were performed including Bar-
tlett’s test to check homogeneity of variance (p ≤ 0.1). If the requirements were met, ANOVA analysis was 
conducted. If the requirements were not fulfilled, the Friedmann test was performed. Probability levels of p ≤ 
0.05 versus control were considered as significant. The data are given as arithmetic means ±  standard deviations 
(mean ±  SD). 
3. Results 
The free intracellular amino and α-keto acid concentrations, superoxide anion formation, hydrogen peroxide 
generation as well as the activity of released myeloperoxidase obtained in the control cells were within normal 
physiological ranges [14] [24] [25]. 
An overview of the intracellular amino and α-keto acid as well as plasma levels, which were found in the 
present survey are presented in Table 1. For example intracellular pyruvate levels amounted on average to 6.72 
× 10−17 moles per neutrophil (PMN) cell (169.1 µmol/L PMN cell volume [NCV]; plasma: 102.9 ±  42.7 µmol/L). 
The intracellular α-ketoglutarate content at almost 1.21 × 10−17 mol per PMN cell (30.5 µmol/L NCV; plasma: 
6.8 ±  2.3 µmol/L) was approximately 5.6 times lower. However, the composition of these free amino acid and 
α-keto acid pools does not appear to be arbitrary in any way. When comparing the intra versus the extracellular 
concentration gradient [i:e], the results painted a very different picture: for pyruvate (i:e: 1.6), glutamine (i:e: 
1.2), alanine (i:e: 1.3), arginine (i:e: 0.9), serine (i:e: 4.1) and glycine (i:e: 2.7) not only high plasma but also 
high intracellular concentrations have been found, while α-ketoglutarate (i:e: 4.5), glutamate (i:e: 40.6), aspar-
tate (i:e: 56.8), asparagine (i:e: 1.7), ornithine (i:e: 2.3) with low plasma concentrations apparently accumulated 
within the neutrophils (Table 1). 
3.1. Effects of PYR Combined with L-NAME, SNAP, DON, β-Ala or DFMO on the Free  
α-Keto Acid Pools in Neutrophils (Figure 1) 
Additional application of SNAP, DON, β-alanine or DFMO to PYR also induced important PYR-independent 
effects. While L-NAME induced no effect exceeding that of singular PYR, significant reductions in 
α-ketoglutarate (PYR: +115%; PYR + SNAP: +62%) and pyruvate (PYR: +205%; PYR + SNAP: +93%) that 
were both clearly raised by singular PYR occurred after SNAP application, although these values remained sig-
nificantly above the respective control values. 
Upon DON application, however, there were significant decreases in all measured α-ketoacids that were be-
low the control findings (α-ketoglutarate: PYR + DON: −26%, pyruvate: PYR + DON: −31% and α-ketobutyrate: 
PYR + DON: −36%). 
Only with the cellular α-ketobutyrate content did β-ala induce additive effects that exceeded singular PYR 
(PYR: +22%; PYR + β-ala: +61%). 
DFMO added to PYR induced a decrease in intragranulocytic α-ketoglutarate (PYR + DFMO versus PYR: 
−34%) and also pyruvate (PYR + DFMO versus PYR: −47%). 
3.2. Effects of PYR Combined with L-NAME, SNAP, DON, β-Ala or DFMO on the Free Amino  
Acid Pools in Neutrophils (Figures 2-8) 
The incubation of PYR with the above described “metabolism modulators”  L-NAME, SNAP, DON, β-Ala or 
DFMO led, unlike singular application, to significant and decisive findings. 
Combined administration of L-NAME and PYR induced no effect that exceeded singular application of PYR.  
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Table 1. Content of free amino acids [10–16  Mol] and α-keto acids [10–17  Mol] per neutrophil (PMN, mean ± 
standard deviation [SD]; n = 10) and their intracellular concentrations based on the mean neutrophil cell volume 
(NCV) [μMol/l, mean ± SD; n = 10]. NCV was calculated as follows: NCV = leukocritsample × PMN-number
−1 
[NCVamino acids: 431.8 ± 211.2 × 10
−15 L, NCVα-keto acids: 397.3 ± 234.8 × 10
−15 L]. Also pictured are the plasma 
concentrations found in this study [μMol/l, mean ± SD; n = 10]. Additionally, the intra (I) versus extracellular (E) 
concentration gradients (I:E) have also been computed.                                                    
Amino acids  
PMN NCV Plasma Gradient 
 
10−16 Mol/cell [µMol/l] [µMol/l] I:E 
  
mean ± SD mean ± SD mean ± SD 
 
aspartate (asp) 2.97 1.14 687.8 264.0 12.1 4.4 56.8 
glutamate (glu) 6.17 1.93 1428.9 447.0 35.2 14.9 40.6 
asparagine (asn) 0.41 0.15 95.7 34.7 57.8 16.6 1.7 
serine (ser) 2.05 0.54 474.8 125.1 115.2 39.1 4.1 
glutamine (gln) 3.27 0.98 757.3 227.0 621.6 234.1 1.2 
histidine (his) 1.03 0.56 238.5 129.7 78.5 27.0 3.0 
glycine (gly) 2.59 0.75 599.8 173.7 226.3 71.8 2.7 
threonine (thr) 0.78 0.26 180.6 60.2 101.4 68.4 1.8 
citrulline (cit) 0.13 0.04 30.1 9.3 29.5 11.2 1.0 
arginine (arg) 0.34 0.08 78.7 18.5 87.8 22.5 0.9 
taurine (tau) 40.8 9.38 9448.8 2172.3 124.9 49.3 75.7 
hypotaurine (h-tau) 1.91 0.65 442.3 150.5 2.4 0.7 184.3 
alanine (ala) 2.24 0.83 518.8 192.2 387.4 169.5 1.3 
tyrosine (tyr) 0.79 0.35 183.0 81.1 71.7 34.9 2.6 
α-aminobutyrate (aba) 0.16 0.10 37.1 23.2 20.3 8.8 1.8 
tryptophane (trp) 0.19 0.11 44.0 25.5 71.2 26.1 0.6 
methionine (met) 0.17 0.12 39.4 27.8 20.2 9.8 1.9 
valine (val) 0.47 0.19 108.8 44.0 185.6 71.4 0.6 
phenylalanine (phe) 1.02 0.64 236.2 148.2 84.9 28.5 2.8 
isoleucine (ile) 0.52 0.17 120.4 39.4 78.4 35.6 1.5 
leucine (leu) 0.83 0.26 192.2 60.2 136.5 86.9 1.4 
ornithine (orn) 0.44 0.12 101.9 27.8 45.1 24.7 2.3 
lysine (lys) 0.56 0.30 129.7 69.5 216.8 89.2 0.6 
α-keto acids  
PMN NCV Plasma Gradient 
 
10−17 Mol/cell [µMol/l] [µMol/l] I:E 
  
mean ± SD mean ± SD mean ± SD 
 
α-ketoglutarate (KG) 1.21 0.31 30.5 7.8 6.8 2.3 4.5 
pyruvate (PYR) 6.72 2.03 169.1 51.1 102.9 42.7 1.6 
α-ketobutyrate (KB) 4.07 1.30 102.4 32.7 8.7 2.9 11.8 
α-ketoisovalerate (KIV) 2.27 1.08 57.1 27.2 18.1 7.5 3.2 
α-ketoisocaproate (KIC) 0.36 0.25 9.1 6.3 37.5 11.4 0.2 
p-OH-phenylpyruvate (PPYR) 0.29 0.18 7.3 4.5 7.6 4.1 1.0 
α-keto-β-methylvalerate (KMV) 0.80 0.49 20.1 12.3 24.2 8.6 0.8 




Figure 1. Effects of pyruvate (1 mM, incubated for 120 min) after a 10 min pre-incubation either with L- 
NAME (1 mM), SNAP (100 µM), DON (100 µM), beta-Ala (10 mM) or DFMO (1 mM) on free intracellular 
α-ketoglutarate, pyruvate and α-ketobutyrate concentrations in neutrophils [PMN] (10−17 moles per PMN- 
cell; mean ± SD; n  = 10). *p ≤ 0.05 versus control values; #p ≤ 0.05 versus pyruvate.                        
 
 
Figure 2. Effects of pyruvate (1 mM, incubated for 120 min) after a 10 min pre-incubation either with L- 
NAME (1 mM), SNAP (100 µM), DON (100 µM), beta-Ala (10 mM) or DFMO (1 mM) on free intracellular 
acidic amino acid (asparagine and glutamine) concentrations in neutrophils [PMN] (10−16 moles per PMN- 
cell; mean ± SD; n  = 10). *p ≤ 0.05 versus control values; #p ≤ 0.05 versus pyruvate.                        
 
 
Figure 3. Effects of pyruvate (1 mM, incubated for 120 min) after a 10 min pre-incubation either with 
L-NAME (1 mM), SNAP (100 µM), DON (100 µM), beta-Ala (10 mM) or DFMO (1 mM) on free intracellu-
lar acidic amino acid (aspartate and glutamate) concentrations in neutrophils [PMN] (10−16 moles per 
PMN-cell; mean ± SD; n  = 10). *p ≤ 0.05 versus control values; #p ≤ 0.05 versus pyruvate.                      




Figure 4. Effects of pyruvate (1 mM, incubated for 120 min) after a 10 min pre-incubation either with L- 
NAME (1 mM), SNAP (100 µM), DON (100 µM), beta-Ala (10 mM) or DFMO (1 mM) on free intracellular 
basic amino acid concentrations (ornithine, arginine, citrulline) in neutrophils [PMN] (10−16 moles per 
PMN-cell; mean ± SD; n  = 10). *p ≤ 0.05 versus control values; #p ≤ 0.05 versus pyruvate.                   
 
 
Figure 5. Effects of pyruvate (1 mM, incubated for 120 min) after a 10 min pre-incubation either with L DON 
(100 µM) or beta-Ala (10 mM) on free intracellular branched chain amin acid concentrations (isoleucine, 
leucine, valine) in neutrophils [PMN] (10−16 moles per PMN-cell; mean ± SD; n  = 10). *p ≤ 0.05 versus con-
trol values; #p ≤ 0.05 versus pyruvate.                                                                       
 
 
Figure 6. Effects of pyruvate (1 mM, incubated for 120 min) after a 10 min pre-incubation either with L DON 
(100 µM) or beta-Ala (10 mM) on free intracellular taurine and hypotaurine concentrations in neutrophils 
[PMN] (10−16 moles per PMN-cell; mean ± SD; n  = 10). *p ≤ 0.05 versus control values; #p ≤ 0.05 versus py-
ruvate.                                                                                       




Figure 7. Effects of pyruvate (1 mM, incubated for 120 min) after a 10 min pre-incubation either with L- 
NAME (1 mM), SNAP (100 µM), DON (100 µM), beta-Ala (10 mM) or DFMO (1 mM) on free intracellular 
neutral amino acid concentrations (serine, glycine) in neutrophils [PMN] (10−16 moles per PMN-cell; mean ± 
SD; n = 10). *p≤ 0.05 versus control values; #p ≤ 0.05 versus pyruvate.                                            
 
 
Figure 8. Effects of pyruvate (1 mM, incubated for 120 min) after a 10 min pre-incubation either with L- 
NAME (1 mM), SNAP (100 µM), DON (100 µM), beta-Ala (10 mM) or DFMO (1 mM) on free intracellular 
neutral amino acid concentrations (threonine, alanine) in neutrophils [PMN] (10−16 moles per PMN-cell; 
mean ± SD; n  = 10). *p ≤ 0.05 versus control values; #p ≤ 0.05 versus pyruvate.                              
 
Although SNAP and PYR in neutrophils, compared with PYR alone, induced significantly lower intracellular 
asparagine (PYR: +90%; PYR+SNAP: +31%), glutamine (PYR: +101%; PYR + SNAP: +48%), aspartate (PYR: 
+95%; PYR + SNAP: +39%), glutamate (PYR: +149%; PYR + SNAP: +69%) alanine and basic amino acids 
levels (ornithine: PYR: +115%; PYR+SNAP: +63%, arginine: PYR: +211%; PYR + SNAP: +94%, citrulline: 
PYR: −8%; PYR+SNAP: +7%), the results were nevertheless still significantly above the control findings. For 
serine (PYR: +43%; PYR + SNAP: +14%), glycine (PYR: +47%; PYR + SNAP: +8%) and threonine (PYR: 
+6%; PYR + SNAP: −7%) as well, SNAP induced a concentration decrease compared to PYR application alone. 
Nevertheless this reduction remained more or less within the range of control values. 
DON produced a very clear reduction in important primary amino acids. Although the contents of cellular 
alanine (PYR: +75%; PYR + DON: −9%) were decreased significantly compared to PYR singular application, 
they were still within control ranges. Regarding the granulocytic asparagine (PYR+DON: −34%), aspartate 
(PYR + SNAP: −29%), glutamine (PYR + SNAP: −41%), glutamate (PYR + SNAP: −27%), branch-chain 
amino acid levels (isoleucine: PYR: −13%; PYR + DON: +34%, leucine: PYR: −8%; PYR + DON: +39%, valine: 
PYR: −4%; PYR + DON: +30%), hypotaurine (but not taurine, PYR: +13%; PYR + DON: −45%), neutral 
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amino acids (serine: PYR + DON: −27%, glycine: PYR + DON: +31%, threoni-ne: PYR + DON: −25%) as well 
as basic amino acid levels (ornithine: PYR + DON: −28%, arginine: PYR + DON: −33%, citrulline: PYR + 
DON: −38%), significant intracellular concentration changes were observed. 
β-Ala in combination with PYR induced significant reductions in granulocytic hypotaurine (PYR + β-Ala: 
−39%) and taurine (PYR + β-Ala: −31%). In addition, β-Ala also exerted additive effects on the content of neu-
tral amino acids (serine: PYR + β-Ala: +91%, glycine: PYR + β-Ala: +104%, threonine: PYR + β-Ala: +53%, 
alanine: PYR + β-Ala: +124%). 
DFMO added to PYR (similar to L-NAME) induced a decrease in intragranulocytic arginine (PYR + DFMO 
versus PYR: −45%) and increase in citrulline (PYR + DFMO versus PYR: +58%) that exceeded the effects of 
singular PYR application. The slight decrease of ornithine was not statistically significant (DFMO added to 
PYR).  
3.3. Effects of PYR Combined with L-NAME, SNAP, DON, β-Ala or DFMO on Neutrophil  
Oxidative Response and Myeloperoxidase Activity (Figure 9) 
PYR led to an increased formation of superoxide anions and hydrogen peroxide and combined with L-NAME 
additional significant increases were observed ( 2O
− : PYR: +155%; PYR + L-NAME versus PYR: +87%; H2O2: 
PYR: +123%; PYR + L-NAME versus PYR: +128%). The activity of myeloperoxidase released by neutrophils 
on the other hand was not influenced by L-NAME application (PYR: +164%). 
In combination with PYR, SNAP and DON induced decreases in superoxide anion and hydrogen peroxide 
generation that were raised by PYR on its own, but DON alone however led to a reduction below control values 
( 2O
− : PYR + DON: −31%; H2O2: PYR + DON: −36%). The “nutritively”-induced increase in myeloperoxidase 
activity was also significantly inhibited by SNAP and DON but the results revealed no differences from control 
findings. 
β-alanine in combination with PYR led to a significant increase in granulocytic superoxide anion production. 
With PYR there were additive effects exceeding effects of singular incubation (PYR + β-Ala versus PYR: 
+39%). Similar effects were seen with hydrogen peroxide formation, where there were also further significant 
increases in the measured values (PYR + β-Ala versus PYR: +67%). Regarding the myeloperoxidase activity, 
the combination of β-alanine and PYR did not lead to significant effects. 
DFMO also produced an inhibition of superoxide anion and hydrogen peroxide formation. The findings ob-
tained here for PYR were completely above the respective control values ( 2O
− : PYR+DFMO versus PYR: −41% 
or versus control: +49%; H2O2: PYR + DFMO versus PYR: −28% or versus control: +62%). 
 
 
Figure 9. Effects of pyruvate (1 mM, incubated for 120 min) after a 10 min pre-incubation either with L- 
NAME (1 mM), SNAP (100 µM), DON (100 µM), beta-Ala (10 mM) or DFMO (1 mM) on PMN superoxide 
anion production [ 2O
− ; fmol/(PMN·min)−1], hydrogen peroxide formation [H2O2; fmol/ (PMN·min)
−1] and 
myeloperoxidase activity [MPO; units/l supernatant]; (mean ± SD; n = 10). *p ≤ 0.05 versus control values; #p 
≤ 0.05 versus pyruvate.                                                                        




It is broadly accepted scientific consensus that not only amino acids (i.e. taurine, glutamine, glutamate, alanine, 
arginine or ornithine) but also α-keto acids (i.e. α-ketoglutarate, pyruvate) appear to have significant metabolic 
and nutritional functions in leukocytes. More than that, the composition of free intracellular amino acid and 
α-ketoacid pools in body cells do not seem to be arbitrary in any direction, but may rather represent a relevant 
metabolic correlate, a quasi-immunonutritional metabolic fingerprint, for the underlying functions [24]-[26]. It is 
thus not surprising that scientific interest here also focused on the possibility to use selected amino- or keto- 
acids as part of a “standard” diet therapeutically [27]-[29]. However, many questions are unfortunately here still 
unclear. For instance, little evidence is available regarding the question what precise pathophysiological me-
chanisms are involved in the effects of pyruvate on PMN substrate and energy supply or their immune functions. 
4.1. Pyruvate Induced Effects: Is There an Impact by Adding a Glutamine-Analogue? 
DON, a wide ranging inhibitor of all glutamine dependent intracellular effects, induced a clear reduction in in-
tragranulocytic glutamine, but also contributed to important changes in pyruvate, α-ketoglutarate or α-ketobu- 
tyrate concentrations. Other important amino acids such as glutamate, aspartate or basic, branched chain of neu-
tral amino acids were also significantly changed. Referring to previous research, it seems clear: the enzymatic 
constellation required for a direct or indirect pyruvate metabolization and synthesis via glutamine-dependent 
intracellular pathways is certainly present in neutrophils as it is in other leukocytes (i.e. reversible transamina-
tions involving the release of NH3, the metabolization via phosphate-dependent glutaminase which in leukocytes 
can be activated by proinflammatory mediators and catecholamines, the conversion of malate to oxalacetate by 
the NADP+-dependent malate dehydrogenase or oxidative glutamate deamination to form ammonium ions, 
which are excreted as urea or also a α-ketoglutarate synthesis from oxaloacetate and glutamate). For example 
α-ketoglutarate, the carbon backbone arising from pyruvate transmission or glutamine oxidation, can imme-
diately be fed into the tricarboxylic acid cycle and through that it is indirectly available to the enzymes of the 
urea cycle, for example in the form of aspartate via oxaloacetate [1]-[3] [30] [31]. So it is not surprising that 
α-ketoglutarate, for example incubated in neutrophils is able to increase cellular substrate storages and immune 
functions [6] [32]. 
Moreover, as shown here, the indirect participation of pyruvate in glutamine metabolisation can also deter-
mine the formation of arginine and ornithine (i.e. catalysed by the enzymes pyrroline-5-carboxylate synthase, 
ornithine aminotransferase, ornithine carbamyltransferase, or carbamylphosphate synthase) or the synthesis of 
•NO which is required for neutrophil activation [33] [34]. And indeed, a growing consensus exists regarding a 
so-called “pyruvate-glutamate-ketoglutarate-arginine-ornithine-system”, which especially in leukocytes, appears 
to hold a key role as an “ intracellular turntable for amino nitrogen metabolisation” [32] [35]. The advantages to 
the cell seems obvious: the possibility of a rapid transition into other essential cell substrates (i.e. acetyl-CoA). 
Interestingly, since the enzyme fructose-1,6-bisphosphatase is also found in neutrophils, pyruvate is also seen as 
an indirect precursor of the de novo synthesis of glucose from pyruvate [36]. 
Nevertheless, it is mostly concurred that only a minuscule proportion of the carbon, arising from pyruvate in-
cubation in neutrophils, is completely oxidized into carbon dioxide (30%). The underlying thesis is, that in ana-
bolic situations not only a raised pyruvate uptake, but also a substantial amount of de novo intracellular pyruvate 
as well as pyruvate-dependent metabolite synthesis occurs [37]-[39]. And indeed, our results seem to confirm 
this hypothesis, because following pyruvate incubation increased glutamate, glutamine, aspartate (asparagine), 
alanine, α-ketotglutarate but also to serine and glycine concentrations have intracellularly been found (i.e. via 
serine- and glycine-hydroxymethyltransferase). This final detail, in particular, is of special importance for neu-
trophils or other leukocytes, because they must suddenly increase their metabolism and substrate turnover in re-
sponse to a stimulus, and that only works if the substrate storages are filled. And the advantage of high intra-
granulocytic pyruvate, glutamine, glutamate, alanine or aspartate levels in the cell is obvious: neutrophils, par-
ticularly in the context of an increased demand or those which are isolated from a direct nutrient supply (i.e. in 
inflammation or tumour areas which per se are substrate depleted areas), can rapidly fall back on relevant meta-
bolic precursors, required for the synthesis of immune-functional enzymes, proteins, amino sugars, RNA and 
DNA or glutathione. Therefore, these cells act both, as immunological fighting machines as well as nutrient 
transporters [40] [41]. 
On the base of our findings and other results available, we therefore believe, that pyruvate plays a crucial 
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function as an immuonutritional energy supplier for leukocyte cells. And in fact, the energy output is high, be-
cause the transition of one molecule of pyruvate via the TCA cycle, together with oxidative phosphorylation, 
produces 15 molecules of ATP as well as NADPH, which can for example be further metabolized by membran-
ous NADPH oxidase (nicotinamide adenine dinucleotide phosphate-oxidase) as well [9] [10] [42]-[44]. Under 
physiological conditions, the complex is inactive and only activated during respiratory burst. But after activating, 
this enzyme system produces enormous amounts of superoxide anion, a reactive free-radical, by transferring 
electrons from NADPH inside the cubicle across the membrane and coupling these with molecular oxygen. Su-
peroxide anion can be produced in phagosomes, which contain ingested bacteria and fungi, or can be utilized as 
an assault weapon for external enemies by inactivation of critical metabolic enzymes, initiation of lipid peroxi-
dation, or liberation of redox-active iron, which permits the generation of indiscriminate oxidants such as the 
hydroxyl radical. In a phagosome as well as in an extracellular matrix, superoxide can spontaneously form hy-
drogen peroxide or hypochlorous acid, also recognised as “reactive oxygen species” (ROS) [30] [45]. And in-
deed, these weapons are disastrous. As studies impressively demonstrated: superoxide is able to kill bacteria di-
rectly, especially when the virulence of the pathogen is dramatically attenuated (i.e. by superoxide dismutase 
deficiency) [46] [47]. Here in this study, the inhibition of specific glutamine-dependent pathways were one im-
portant constituent in the significant turnaround of the pyruvate-induced alterations in the immune parameters 
examined. We thus strongly suggest that in neutrophils a) pyruvate appears to run a relevant immunonutrional 
role and b) pyruvate- and glutamine-dependent pathways seem connected to each other. 
4.2. Pyruvate Induced Effects: Is There an Impact by Adding an Inhibitor of •NO-Synthase,  
an •NO Donor or an Inhibitor of Ornithine-Decarboxylase? 
Significant alterations of the pyruvate induced effects on the parameters observed here was also followed after a 
pre-incubation with an •NO donor which artificially-induced an extracellular •NO increase over the micromolar 
concentration range. For pyruvate itself, but also for α-ketoglutarate glutamine, glutamate, ornithine, arginine or 
citrulline a significant reduction of the pyruvate-induced effects could be noticed, although the drop did not de-
crease under the initial points. Parallel results were likewise found for superoxide anion and hydrogen peroxide 
generation.  
Regarding possible causes we believe— in line with other investigators— that it is probably a combination of 
different mechanisms may here be responsible for the interesting effects (i.e. the inhibition of specific pyru-
vate-dependent intracellular metabolic functions, a •NO-mediated transmembranous amino or α-keto acid loss, a 
•NO-mediated influencing by enzymes of the citric acid cycle [i.e. cis-aconitase (, etc.), but the real biochemical 
background is yet not entirely realised [30] [45]. 
But in terms of the investigated immune parameters, a potential explanation may be found: in neutrophils, 
•NO seems directly to be involved in different mechanisms which controls the vital balance between oxygen 
radical metabolites in the regulation of inflammatory processes. For example, via inhibition of the NADPH oxidase 
complex, an inhibition of •NO synthase, an •NO-mediated influencing of enzymes of the respiratory chain or via 
an •NO concentration-dependent inhibition of ribonucleotide reductase [DNA synthesis, ADP-ribosyltransferase 
or glyceraldehyde-3-phosphate-dehydrogenase (glycolysis and gluconeogenesis)]. And the profit for the cell 
seems here to be clear: these mechanisms help to protect against the danger of self-destruction and the growth of 
an unruly, self-reinforcing immune response [20] [48]-[50]. And this, in the end, protects all cells of the in-
flammatory matrix against uncontrolled tissue destruction [51]. 
Moreover, the outcomes of our study also showed, that pre-incubation with an ornithine decarboxylase inhi-
bitor, led to a modulation of the pyruvate induced effects, as well. We therefore must assume, that in neutrophils 
inhibition of intracellular ornithine metabolism also seems to possess a considerable influence on intracellular 
amino- and keto acid metabolism as well as essential immune functions [52]. The most convincing hypothesis to 
explain these findings is, that in neutrophils and other leukocytes ornithine seems to be employed as a substrate 
for polyamine synthesis, which are essential metabolic components for virtually all cell types with high cell di-
vision rates and stimulable metabolic activities [53] [54]. It is believed that polyamines may have specific roles 
in cellular protein biosynthesis, growth, proliferation and apoptosis processes, for instance through the stabiliza-
tion of cellular DNA and RNA through the binding of spermine and spermidine. And equally in other leukocytes, 
the need for polyamines is covered by both, transport from the extracellular matrix (here the capacity in leuko-
cytes is low) as well as synthesis (spermine synthesis after enzymatic decarboxylation of ornithine by orni-
thine-decarboxylase) [55]-[59]. Nevertheless, their precise metabolic functions in human neutrophils are still 




Concerning free amino- and α-keto acid pools as well as myeloperoxidase activity in neutrophils, an inhibitor 
of •NO-synthase (i.e. L-NAME) induced no further effects, but led to significant increases in the formation of 
superoxide anions and hydrogen peroxide. For this reason we think that metabolic alterations are probably not 
the main cause of these effects. With regard to possible causes, the following hypotheses are currently discussed: 
a potential influence on the transmembranous arginine transport (accompanied by a decrease in intracellular ar-
ginine content) and/or •NO-synthase independent mechanisms (i.e. through a direct reaction of arginine with 
H2O2, etc.). But in the authors’ opinion, it is also conceivable that these findings, again, only indicate a critical 
balance and negative feedback mechanism to balance oxygen radical metabolites and •NO-production as a pro-
tective against self-destruction [60]-[62]. This theory, indeed, could further explain some other confusing bi-
phasic findings previously found: while low •NO and peroxynitrite concentrations were able to induce PMN- 
activation (i.e. detectable by raising production of superoxide anions and hydrogen peroxide), high •NO concen-
trations and the follow-on product, peroxynitrite or other reactive nitrogen metabolites— which can no longer be 
scavenged by the oxygen radicals in the extracellular matrix— reverse this process [63]. Interestingly, these ef-
fects seem to be multifactorial here (i.e. perhaps via a •NO-dose-dependent inhibition of reduction of superoxide 
anion generation and NADPH oxidase complex or •NO synthase β-glucuronidase secretion and leukotriene for-
mation) [47]. On the other hand, nevertheless, an inhibition of •NO-synthesis combined with an immunonutri-
tion of neutrophils (i.e. Using pyruvate) leads to a substantial growth of oxygen free radicals that cannot be fur-
ther metabolized by •NO [64] [65]. Our assumption is therefore: the L-NAME-induced further changes in supe-
roxide anion and hydrogen peroxide formation may not primarily represent an activation of neutrophils, but 
seems simply to reflect a reduced conversion of NO and oxygen radicals to further metabolites (i.e. peroxynitrite, 
etc.) [48] [60] [63]. 
4.3. Pyruvate Induced Effects: Is There an Impact by Adding a Taurine  
Transport Antagonist? 
The results of this study additionally showed, that pyruvate had no influence on the taurine and hypotaurine 
content, only the loudness of the taurine-hypotaurine-amino acid transport system (i.e. following pre-incubation 
with β-alanine) led to significant decreases in intragranulocytic taurine and hypotaurine concentrations (inters-
tingly, very similar effects were observed after incubation with DON) as well as resulted to parallel increases in 
intracellular neutral amino acids and α-ketobutyrate (which are metabolically related to threonine). Touching on 
the PMN immune parameters observed here, β-alanine, in combination with pyruvate, led to further additive ef-
fects in granulocytic superoxide anion production and hydrogen peroxide formation, but simply possessed no in-
fluence on the activity of myeloperoxidase. 
Adverting to the interesting new results we believe that a modulation of relevant taurine-dependent trans-
membraneous transport mechanisms are the most likely explanation for the changes in intragranulocyte taurine 
concentrations. But only a simple homeostatic response to modifications in intragranulocytic amino- and α-keto 
acid homeostasis or metabolism can also not be excludedt [5] [66]. These novel results, again, support the hy-
pothesis that compositional modifications in neutrophil taurine concentrations appear to affect the composition 
of the intragranulocytic amino- and α-keto acid pools but certainly influences the magnitude and the character of 
their immune response. Not least the exceptional high taurine concentrations in neutrophils compared with other 
leukocytes, seem to support this hypothesis [67]-[69]. 
5. Conclusion 
In summary, the interesting results presented here showed, that any damage of specific pathways or mechanisms, 
which seem directly or indirectly connected to pyruvate conversion-dependent cellular tasks, led to significant 
immunonutritional alterations in the affected PMN-cells. We thus believe that pyruvate, irrespective of which 
exact biochemical mechanisms were involved, may satisfy the substantial metabolic demands for a potent intra-
cellular nutrient. With respect to a clinical therapy, but there are problems: pyruvate is relatively unstable in 
aqueous solution and the hunt for a possible alternative here currently led, for example, to the development of 
ethyl pyruvate, which is a simple aliphatic ester derived from pyruvate, but as well contributed to the invention 
of stable aqueous solutions containing sodium pyruvate using H+ (pH 3.0 - 6.0) or additional Na+ (20 mM) [22] 
[70]-[72]. And in fact, the first results seem to be promising: treatment with pyruvate or ethyl pyruvate has 
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shown to improve survival and/or ameliorate organ dysfunction in a wide variety of pre-clinical models or 
clinical trials of acute illnesses such as severe sepsis, acute pancreatitis, respiratory distress syndromes, stroke, 
cancer or in patients undergoing cardiac surgery [18] [35] [70]-[79]. Furthermore, the therapy using pyruvate or 
pyruvate-related compounds was also shown to be safe, but, nevertheless, in most studies it failed to improve 
outcome. So, we believe that the following consideration could play an important function here: concerning any 
immunonutritional therapy using pyruvate or derivatives, one should bear in mind that any maintaining or in-
creasing of a granulocytic metabolic function or any improvement of granulocyte specific immunological 
weapons must not inevitably contribute to a clinical improvement of the disease outcome; and especially not in 
critically ill patients. This certainly surprising thesis can partially be explained by the pathophysiological prob-
lem that arises when immunonutritionally strengthened neutrophils migrate into an inflammatory nutrient de-
pleted, and thereby potentially weakened, extravascular matrix. Here, in that location is indeed a substantial 
hazard of an additional granulocyte-mediated cell and tissue trauma. Immunonutrition using pyruvate or pyru-
vate derived chemical compounds (e.g. ethyl-pyruvate), may therefore possess a dual-headed nature, best sym-
bolised by “Janus”, the god of beginnings and transitions, gates, doorways, endings and time [32] [40] [80]-[82]. 
In our view, more research activity seems to be necessary and useful to conclusively clarify the important 
therapeutic question: Is a therapy, using pyruvate or pyruvate derived chemical compounds, really secure and 
beneficial for our patients? 
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